Jump to: Page Content, Site Navigation, Site Search,
You are seeing this message because your web browser does not support basic web standards. Find out more about why this message is appearing and what you can do to make your experience on this site better.
BMJ 2003;327:5-6 (5 July), doi:10.1136/bmj.327.7405.5
Despite limitations, overall evidence shows that point of care testing is reliable
| The first 150 words of the full text of this article appear below. |
The development and adoption of instruments for determining the international normalised ratio (INR) at the point of care for monitoring treatment with coumarin anticoagulants has added another variable to the question of the precision of INR measurements. In this issue Poller et al (p 30) show discrepancies between results when two such instruments are used and the best estimate of the true INR.1 These observations, however, should be seen in the context of the already recognised limitations of the INR system and the potential for using point of care testing to deliver safe and effective anticoagulant therapy efficiently.
Coumarin anticoagulants remain the preferred method of prophylaxis and
treatment for thrombosis in a range of clinical situations. Around 1% of the
populations of many countries receive such treatment, a proportion boosted by
the increasing use of oral anticoagulation as thromboprophylaxis in atrial
fibrillation.2
Monitoring of the anticoagulant effect of
ET Murray, research fellow
Department of General Practice, University of Birmingham, Edgbaston, Birmingham B15 2TT
M Greaves, professor
Department of Medicine and Therapeutics, University of Aberdeen, Aberdeen AB25 2ZD
Read all Rapid Responses